Cellares Completes First cGMP Cell Shuttle at New Jersey Facility

• Cellares has completed its first cGMP Cell Shuttle at its IDMO Smart Factory in Bridgewater, New Jersey.

• The facility will produce up to 40,000 CAR-T cell therapy doses annually, using advanced automation systems.

Cellares, an Integrated Development and Manufacturing Organization (IDMO), has completed the first cGMP Cell Shuttle at its Smart Factory in Bridgewater, New Jersey. This marks a key milestone for the facility, which aims to produce up to 40,000 standard CAR-T cell therapy doses annually.

The Bridgewater facility is designed to streamline cell therapy manufacturing through advanced automation systems, including the Cell Shuttle and Cell Q. These technologies automate key processes, including quality control and electronic batch record generation, to improve efficiency and reduce human error.

Cellares plans to expand its network of IDMO Smart Factories in the future, both in the U.S. and abroad, to meet rising demand for cell therapies.

CEO Fabian Gerlinghaus commented, “Bringing our first cGMP Cell Shuttle online in New Jersey is a major step for Cellares and our partners. This facility showcases our innovative approach and aligns with our mission to provide life-saving cell therapies to patients in need, faster and more efficiently than ever.”

Cellares’ Bridgewater facility is expected to provide partners with enhanced scalability, cost-effectiveness, and speed, while maintaining high standards of safety and quality in cell therapy production.